


**Figure 6. Clinical Question 5 “Group 4”**



\*Comment: It is uncertain whether patients with  $\geq 4.0$  and  $< 6.0$  average *HER2* signals/cell and *HER2/CEP17* ratio  $< 2.0$  benefit from *HER2* targeted therapy in the absence of protein overexpression (IHC 3+). If the specimen test result is close to the ISH ratio threshold for positive, there is a higher likelihood that repeat testing will result in different results by chance alone. Therefore, when IHC results are not 3+ positive, it is recommended that the sample be considered *HER2* negative without additional testing on the same specimen.